Botulinum toxin in poststroke spasticity

Clinical Medicine and Research

Volumn 5, Issue 2, 2007, Pages 132-138

  Ozcakir, Suheda ^a   Sivrioglu, Koncuy ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Botulinum toxin; Spasticity; Stroke

Indexed keywords

ALCOHOL; BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; MUSCLE RELAXANT AGENT; PHENOL; PLACEBO; ANTIPARKINSON AGENT;

ACETYLCHOLINE RELEASE; ARTHRODESIS; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFUSION; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSPHAGIA; ELECTROSTIMULATION; EXERCISE; FUNCTIONAL ASSESSMENT; HEMIPARESIS; HUMAN; LOW DRUG DOSE; LOWER LIMB SPASTICITY; MICTURITION; MOBILIZATION; MULTIPLE CYCLE TREATMENT; MUSCLE TONE; MUSCLE WEAKNESS; NAUSEA; NEUROLYSIS; NEUROMUSCULAR TRANSMISSION; OUTCOME ASSESSMENT; PATIENT POSITIONING; PERSONAL HYGIENE; PHYSIOTHERAPY; RANGE OF MOTION; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SPASTICITY; SPLINT; STRETCHING; STROKE; TREATMENT DURATION; UPPER LIMB SPASTICITY; URINE RETENTION; VOMITING; WALKING; WEAKNESS; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; MUSCLE SPASTICITY; STROKE;

EID: 38949130542     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2007.716     Document Type: Review

References (63)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago, NY: Yearbook Medical; 1980. 485-494.
2. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997;6:S1-S13.
3. Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther 2004;84:973-981.
4. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28:140-175.
5. McCrea PH, Eng JJ, Willms R. Phenol reduces hypertonia and enhances strength: a longitudinal case study. Neurorehabil Neural Repair 2004;18:112-116.
6. Jang SH, Ahn SH, Park SM, Kim SH, Lee KH, Lee ZI. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil 2004;85:506-508.
7. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099-2109.
8. Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003;84:1194-1199.
9. Rayan GM, Young BT. Arthrodesis of the spastic wrist. J Hand Surg [Am] 1999;24:944-952.
10. Keenan MA, Ure K, Smith CW, Jordan C. Hamstring release for knee flexion contracture in spastic adults. Clin Orthop Relat Res 1988;(236):221-226.
11. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl 1997;6:S129-S145.
12. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-1049.
13. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, Wissel J, Yakovleff A. Use of botulinum toxin type A in management of adult spasticity - a European consensus statement. J Rehabil Med 2003;35:98-99.
14. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53:3-9.
15. Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin 2004;44:147-163.
16. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003;21:476-480.
17. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
18. Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 2006;9:121-125.
19. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005;65:765-767.
20. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002;18:S182-S190.
21. Pathak MS, Nguyen HT, Graham HK, Moore AP. Management of spasticity in adults: practical application of botulinum toxin. Eur J Neurol 2006;13:42-50.
22. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004;83:S30-S37.
23. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 1997;6:S208-S220.
24. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19:S92-S100.
25. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 2002;47:118-121. as Phys
26. Barnes MP, Best D, Kidd L, Roberts B, Stark S, Weeks P, Whitaker J. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences. Eur J Neurol 2005;12:947-955.
27. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005;20:1152-1160.
28. Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-1561.
29. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005;37:252-257.
30. Hesse S, Friedrich H, Domasch C, Mauritz KH. Botulinum toxin therapy for upper limb flexor spasticity: preliminary results. J Rehab Sci 1992;5:98-101.
31. Reiter F, Danni M, Ceravolo MG, Provinciali L. Disability changes after treatment of upper limb spasticity with botulinum toxin. J Neurol Rehab 1996;10:47-52.
32. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-35.
33. Sampaio C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Caldas A. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997;11:3-7.
34. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-207.
35. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310.
36. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-388.
37. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
38. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
39. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221.
40. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-565.
41. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
42. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85:705-709.
43. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-1069.
44. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-184.
45. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C; BOTOX Poststroke Spasticity Study Group. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971-1973.
46. Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-1561.
47. Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002;81:272-278.
48. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84.
49. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002;16:654-660.
50. Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004;75:1547-1551.
51. Carda S, Molteni F. Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study. Clin Rehabil 2005;19:621-626.
52. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-363.
53. Gracies JM, Weisz DJ, Yang BY, Flanagan S, Simpson DM. Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol 2002;52:S87.
54. Dengler R, Neyer U, Wohlfarth K, Bettig U, Janzik HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992;239:375-378.
55. Hesse S, Lucke D, Malezic M, Bertelt C, Friedrich H, Gregoric M, Mauritz KH. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-1324.
56. Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996;27:455-460.
57. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40.
58. Bayram S, Sivrioglu K, Karli N, Ozcan O. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil 2006;85:75-81.
59. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, Mazaux JM, Bioulac B, Barat M, Lagueny A. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269.
60. Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998;79:532-535.
61. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998;77:510-515.
62. Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil 2004;85:902-909.
63. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006;87:786-792.